Table 2.
Meta-analysis results for the p53 codon 72 polymorphism and lung cancer risk
| Group/subgroup | Cases/controls | Odds ratio | I 2 (%) | P H | |
|---|---|---|---|---|---|
| OR [95 %CI] | P OR | ||||
| Total studies | 7,929/5,924 | ||||
| Pro allele vs. Arg allele | 1.11 [1.00–1.24] | 0.062 | 70.6 | <0.001 | |
| Pro/Pro vs. Arg/Arg | 1.23 [0.98–1.54] | 0.077 | 70.9 | <0.001 | |
| Arg/Pro vs. Arg/Arg | 1.07 [0.99–1.16] | 0.072 | 21.9 | 0.216 | |
| Arg/Pro + Pro/Pro vs. Arg/Arg | 1.14 [1.07–1.23] | <0.001 | 32.6 | 0.115 | |
| Pro/Pro vs. Arg/Arg + Arg/Pro | 1.22 [0.98–1.53] | 0.073 | 76.2 | <0.001 | |
| Hospital-based studies | 699/819 | ||||
| Pro allele vs. Arg allele | 0.97 [0.84–1.12] | 0.687 | 0.0 | 0.606 | |
| Pro/Pro vs. Arg/Arg | 0.93 [0.69–1.27] | 0.655 | 0.0 | 0.460 | |
| Pro/Arg vs. Arg/Arg | 0.95 [0.76–1.19] | 0.666 | 28.1 | 0.244 | |
| Pro/Arg + Pro/Pro vs. Arg/Arg | 0.95 [0.77–1.18] | 0.631 | 0.0 | 0.550 | |
| Pro/Pro vs. Arg/Arg + Pro/Arg | 0.98 [0.75–1.28] | 0.887 | 44.2 | 0.146 | |
| Population-based studies | 6,228/4,420 | ||||
| Pro allele vs. Arg allele | 1.16 [0.99–1.35] | 0.059 | 77.7 | <0.001 | |
| Pro/Pro vs. Arg/Arg | 1.32 [0.97–1.78] | 0.073 | 77.6 | <0.001 | |
| Arg/Pro vs. Arg/Arg | 1.08 [0.99–1.18] | 0.077 | 28.2 | 0.193 | |
| Arg/Pro + Pro/Pro vs. Arg/Arg | 1.17 [1.07–1.27] | <0.001 | 42.1 | 0.087 | |
| Pro/Pro vs. Arg/Arg + Arg/Pro | 1.32 [0.98–1.77] | 0.069 | 81.8 | <0.001 | |
| Histological types | |||||
| SC | 1,062/3,199 | ||||
| Pro allele vs. Arg allele | 0.99 [0.65–1.50] | 0.951 | 92.0 | <0.001 | |
| Pro/Pro vs. Arg/Arg | 0.96 [0.40–2.28] | 0.919 | 91.6 | <0.001 | |
| Arg/Pro vs. Arg/Arg | 1.04 [0.88–1.23] | 0.648 | 44.4 | 0.145 | |
| Arg/Pro + Pro/Pro vs. Arg/Arg | 1.06 [0.75–1.49] | 0.762 | 74.1 | 0.009 | |
| Pro/Pro vs. Arg/Arg + Arg/Pro | 0.94 [0.52–1.69] | 0.827 | 86.8 | <0.001 | |
| AC | 1,602/3,199 | ||||
| Pro allele vs. Arg allele | 1.01 [0.84–1.21] | 0.935 | 65.7 | 0.033 | |
| Pro/Pro vs. Arg/Arg | 1.17 [0.96–1.44] | 0.125 | 59.7 | 0.059 | |
| Arg/Pro vs. Arg/Arg | 1.02 [0.88–1.19] | 0.805 | 11.3 | 0.336 | |
| Arg/Pro + Pro/Pro vs. Arg/Arg | 1.05 [0.91–1.21] | 0.491 | 49.2 | 0.116 | |
| Pro/Pro vs. Arg/Arg + Arg/Pro | 1.03 [0.73–1.47] | 0.853 | 71.2 | 0.002 | |
| Smoking status | |||||
| Smokers | 2,139/1,868 | ||||
| Pro allele vs. Arg allele | 0.92 [0.66–1.27] | 0.595 | 85.5 | <0.001 | |
| Pro/Pro vs. Arg/Arg | 0.86 [0.45–1.65] | 0.642 | 85.7 | <0.001 | |
| Arg/Pro vs. Arg/Arg | 0.95 [0.79–1.13] | 0.561 | 0.0 | 0.552 | |
| Arg/Pro + Pro/Pro vs. Arg/Arg | 1.06 [0.91–1.25] | 0.528 | 28.6 | 0.240 | |
| Pro/Pro vs. Arg/Arg + Arg/Pro | 1.08 [0.68–1.71] | 0.744 | 82.7 | <0.001 | |
| Nonsmokers | 1,247/2,139 | ||||
| Pro allele vs. Arg allele | 1.04 [0.92–1.18] | 0.521 | 48.3 | 0.102 | |
| Pro/Pro vs. Arg/Arg | 1.15 [0.90–1.46] | 0.272 | 0.0 | 0.521 | |
| Arg/Pro vs. Arg/Arg | 0.77 [0.52–1.15] | 0.207 | 64.7 | 0.023 | |
| Arg/Pro + Pro/Pro vs. Arg/Arg | 0.86 [0.61–1.20] | 0.371 | 59.3 | 0.043 | |
| Pro/Pro vs. Arg/Arg + Arg/Pro | 1.24 [0.89–1.74] | 0.195 | 42.6 | 0.083 | |
OR odds ratio, 95 %CI 95 % confidence interval, P H P value of heterogeneity analysis, SC squamous cancer, AC adenocarcinoma